• Earlier this month, ImmunityBio, Inc. appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman, creating an Office of the Executive Chairman to concentrate on global strategy, partnerships, and international access to the company’s immunotherapy platform and approved therapies outside the United States.
• By adding a leader with deep experience in global health and multilateral institutions, ImmunityBio is signaling an intent to deepen its engagement with governments and public health agencies, which could shape how its therapies are introduced and accessed in international markets.
• Next, we’ll assess how Dr. Jim Yong Kim’s global health expertise could influence ImmunityBio’s investment narrative and international growth ambitions.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe that ANKTIVA can expand beyond its current bladder cancer and early international approvals into a broader, durable immunotherapy franchise, while the company manages heavy cash burn and losses. Dr. Jim Yong Kim’s appointment looks more relevant to long term global access than to the immediate regulatory and commercialization milestones that still appear to be the key near term catalysts and risks.

The most relevant recent announcement alongside this governance change is the second quarter 2026 result, which showed revenue of US$51.24 million and a net loss of US$230.38 million. Against this backdrop of growing sales but deepening losses, bringing in global health expertise highlights the tension between ImmunityBio’s international ambitions and the financial strain of scaling a broad platform from a still concentrated revenue base.

Yet while global expansion sounds promising, investors should also be aware that...

ImmunityBio's narrative projects $1.6 billion revenue and $673.2 million earnings by 2029. This requires 125.9% yearly revenue growth and a $1.53 billion earnings increase from -$854.5 million today.

Uncover how ImmunityBio's forecasts yield a $13.00 fair value, a 72% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenues could reach about US$1.7 billion and earnings about US$734 million by 2029, which is far more aggressive than the baseline narrative and could be tested by how effectively ImmunityBio executes international expansion and manages its sizeable losses.

Explore 7 other fair value estimates on ImmunityBio - why the stock might be worth just $11.44!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.